Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.1 USD | +0.39% | -0.70% | -21.22% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- With an expected P/E ratio at 186.68 and 12.35 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.54 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.19% | 79.55B | B- | ||
+43.64% | 754B | C+ | ||
+39.48% | 630B | B | ||
-6.58% | 352B | C+ | ||
+19.72% | 331B | B- | ||
+8.78% | 298B | C+ | ||
+11.61% | 217B | B- | ||
-1.96% | 216B | A+ | ||
+0.03% | 163B | C+ | ||
+6.13% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GILD Stock
- Ratings Gilead Sciences, Inc.